Funding for this research was provided by:
Text and Data Mining valid from 2018-08-03
Received: 30 January 2018
Accepted: 9 July 2018
First Online: 3 August 2018
Ethics approval and consent to participate
: The study was reviewed and granted approval from one of RTI International’s institutional review boards. All participants provided written, informed consent.
: Not applicable.
: DW, SRC, and LD are employees of RTI Health Solutions. RTI Health Solutions received funding from Amgen Inc. for the conduct of this study and for the preparation of the manuscript.GG is an employee and shareholder of Amgen Inc.ET is an employee of AstraZeneca.JB received an honorarium for advising on the study.DP has stock/stock options from AKL Research and Development Ltd. which produces phytopharmaceuticals, owns 74% of the social enterprise Optimum Patient Care Ltd., UK and 74% of Observational and Pragmatic Research Institute Pte Ltd., Singapore, and has received grants and unrestricted funding for investigator-initiated studies from Aerocrine, AKL Research and Development Ltd., AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Meda, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva; fees for board membership from Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; consultancy fees from Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; fees for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, Takeda, and Teva Pharmaceuticals; fees for manuscript preparation from Mundipharma and Teva Pharmaceuticals; payments for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva; payment for the development of educational materials from Mundipharma and Novartis; and non-financial support from Efficacy and Mechanism Evaluation programme, Health Technology Assessment, and Medical Research Council.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.